Dasatinib: all 282 studies that test it
Page 1 of 3. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- Asciminib Frontline Risk AdaptedNot yet recruitingNCT07804901Phase 2
- Dasatinib for HIV-1 Reservoir ReductionRecruitingNCT07342491Phase 1
- Senolytics for Secondary Progressive MSNot yet recruitingNCT07270120Phase 1
- Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseRecruitingNCT07269470Phase 2
- Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual DiseaseRecruitingNCT07025226Early Phase 1
- Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06940297Phase 2
- Newly-diagnosed Pediatric T-cell ALL ProtocolRecruitingNCT06855810Phase 2/3
- Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and LymphomaRecruitingNCT06533748Phase 2
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingNCT06390319Phase 2
- Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerRecruitingNCT06355037Phase 2
- Ma-Spore ALL 2020 StudyRecruitingNCT06336395Phase 2
- Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in KoreaRecruitingNCT06257394Phase 2
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT06124157Phase 2
- Bioequivalence Studies of Dasatinib 100 MgNot yet recruitingNCT05944783Phase 4
- HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05751044Phase 1/2
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
- Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older SubjectsRecruitingNCT05653258Phase 2/3
- A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
- Pilot Trial for Treatment of Recurrent GlioblastomaRecruitingNCT05432518Early Phase 1
- COAST Therapy in Advanced Solid Tumors and Prostate CancerRecruitingNCT05036226Phase 1/2
- Asciminib Roll-over StudyRecruitingNCT04877522Phase 4
- Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationRecruitingNCT04838041Phase 2
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)RecruitingNCT04747912Phase 2
- Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic DiseaseRecruitingNCT03844360Phase 4
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLRecruitingNCT03595917Phase 1
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
- Senescence in Chronic Kidney DiseaseEnrolling by invitationNCT02848131Phase 2
- Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's DiseaseCompletedNCT05422885Phase 1/2Results posted
- Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the BodyTerminatedNCT05198843Phase 1/2Results posted
- Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older HumansCompletedNCT04313634Phase 2Results posted
- Dasatinib In Waldenström MacroglobulinemiaTerminatedNCT04115059Phase 1Results posted
- Senolytic Therapy to Modulate Progression of Alzheimer's DiseaseCompletedNCT04063124Phase 1/2Results posted
- Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) AlterationsTerminatedNCT03352427Phase 2Results posted
- Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar RhabdomyosarcomaTerminatedNCT03041701Phase 1/2Results posted
- Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR MutationsTerminatedNCT02954523Phase 1/2Results posted
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsCompletedNCT02883049Phase 3Results posted
- Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaTerminatedNCT02819804Phase 1Results posted
- An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT02750514Phase 2Results posted
- Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFRTerminatedNCT02720185Phase 2Results posted
- Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid LeukemiaTerminatedNCT02709083Phase 2Results posted
- Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic CholangiocarcinomaCompletedNCT02428855Phase 2Results posted
- Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaTerminatedNCT02420717Phase 2Results posted
- Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating DasatinibCompletedNCT02297139Phase 2Results posted
- The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)CompletedNCT02269267Phase 2Results posted
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaActive, not recruitingNCT02143414Phase 2Results posted
- Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal CancerTerminatedNCT02059265Phase 2Results posted
- Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)CompletedNCT01999985Phase 1Results posted
- Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid LeukemiaTerminatedNCT01876953Phase 1/2Results posted
- Dendritic Cell Vaccines + Dasatinib for Metastatic MelanomaCompletedNCT01876212Phase 2Results posted
- Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular ResponseCompletedNCT01850004Phase 2Results posted
- Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to ImatinibCompletedNCT01660906Phase 4Results posted
- Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic AdenocarcinomaCompletedNCT01652976Phase 2Results posted
- Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
- Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to ImatinibCompletedNCT01593254Phase 2Results posted
- Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF MutationTerminatedNCT01514864Phase 2Results posted
- An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)TerminatedNCT01498445Phase 1/2Results posted
- Dasatinib in Advanced Squamous Cell Lung CancerTerminatedNCT01491633Phase 2Results posted
- Cetuximab and Dasatinib in Recurrent Squamous Cell CarcinomaTerminatedNCT01488318Phase 2Results posted
- Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast CancerCompletedNCT01471106Phase 2Results posted
- Pediatric Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT01460160Phase 2Results posted
- Dasatinib in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT01441882Phase 2Results posted
- Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic CancerCompletedNCT01395017Phase 2Results posted
- Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC PatientsCompletedNCT01306942Phase 1/2Results posted
- Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With DocetaxelCompletedNCT01260688Phase 2Results posted
- Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT01256398Phase 2Results posted
- Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted TherapiesCompletedNCT01254864Phase 2Results posted
- Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01238211Phase 2Results posted
- Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLLTerminatedNCT01173679Phase 2Results posted
- Rollover Study of BMS-354825 in Patients With CML and Ph+ALLCompletedNCT01030718Phase 1/2Results posted
- Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00982488Phase 2Results posted
- Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic StudyCompletedNCT00978731Phase 1Results posted
- A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00949988Phase 1/2Results posted
- Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)TerminatedNCT00948389Phase 1/2Results posted
- Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast CancerCompletedNCT00924352Phase 1/2Results posted
- A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT00918463Phase 2Results posted
- Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate CancerTerminatedNCT00918385Phase 2Results posted
- Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast CancerTerminatedNCT00903006Phase 1/2Results posted
- Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma MultiformeCompletedNCT00892177Phase 2Results posted
- Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00869401Phase 1/2Results posted
- Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate CancerTerminatedNCT00860158Phase 2Results posted
- Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland TumorsCompletedNCT00859937Phase 2Results posted
- Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target ModulationTerminatedNCT00858403Phase 2Results posted
- Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by SurgeryTerminatedNCT00835679Early Phase 1Results posted
- Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00826449Phase 1/2Results posted
- Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194CompletedNCT00820170Phase 1/2Results posted
- Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer PatientsTerminatedNCT00817531Phase 2Results posted
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic LeukemiaActive, not recruitingNCT00792948Phase 2Results posted
- Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid TumorsTerminatedNCT00788125Phase 1/2Results posted
- Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLCTerminatedNCT00787267Phase 2Results posted
- Personalized Treatment Selection for Metastatic Breast CancerTerminatedNCT00780676Phase 2Results posted
- A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to ImatinibCompletedNCT00777036Phase 2Results posted
- Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast CancerCompletedNCT00767520Phase 2Results posted
- Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary FibrosisCompletedNCT00764309Phase 1/2Results posted
- Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase InhibitorCompletedNCT00754325Phase 2Results posted
- Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate CancerCompletedNCT00744497Phase 3Results posted
- Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00720109Phase 2/3Results posted
- Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the BladderCompletedNCT00706641Not applicableResults posted
- Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By SurgeryCompletedNCT00700882Phase 2Results posted
- Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or MetastaticCompletedNCT00696072Phase 2Results posted
- A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaCompletedNCT00671788Phase 2Results posted